CervoMed【CRVO】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

13.45

買値

12.49

売値

14.00

出来高

56,689

12.60 日の範囲 14.17

5.85 52 週間の範囲 26.3789

時価総額

111.013M

前日終値

13.65

始値

13.87

時刻

13.44

最終取引時間

財務取引量

US$ 737,818

VWAP

13.0152

平均取引量 (3 か月)

81,375

発行済株式数

8,253,741

配当利回り

PER

-16.72

1 株当たり利益 (EPS)

-0.26

歳入

7.15M

純利益

-2.17M

Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is tran... Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.cervomed.com

本社

Wilmington, Delaware, USA

設立

CervoMed Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker CRVO. The last closing price for CervoMed was US$13.65. Over the last year, CervoMed shares have traded in a share price range of US$ 5.85 to US$ 26.3789.

CervoMed currently has 8,253,741 shares in issue. The market capitalisation of CervoMed is US$112.66 million. CervoMed has a price to earnings ratio (PE ratio) of -16.72.

Form 8-K - Current report

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC...

Form 8-K - Current report

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients • 96% of...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.8	6.32411067194	12.65	14.6215	12.57	85694	13.68624873	CS
4	0.07	0.523168908819	13.38	14.9999	11.9	70808	13.31501235	CS
12	1.75	14.9572649573	11.7	20.63	10.84	81375	15.05794572	CS
26	-11.09	-45.1915240424	24.54	25.69	10.57	74034	16.12286561	CS
52	4.39	48.4547461369	9.06	26.3789	5.85	47817	16.04314887	CS
156	-0.05	-0.37037037037	13.5	26.3789	4.22	50953	13.94930748	CS
260	-0.05	-0.37037037037	13.5	26.3789	4.22	50953	13.94930748	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
VSTEVast Renewable Ltd	US$ 4.98 (149.00%)	68.54M
INVZWInnoviz Technologies Ltd	US$ 0.096 (96.71%)	22.71k
CDXCChromaDex Corporation	US$ 5.87 (68.19%)	37.88M
ATHAAthira Pharma Inc	US$ 0.606 (41.56%)	239.63M
TILEInterface Inc	US$ 23.24 (33.03%)	2.16M
EPIXESSA Pharma Inc	US$ 1.45 (-72.12%)	34.3M
ELABElevai Labs Inc	US$ 0.0288 (-51.19%)	202.28M
OSTOstin Technology Group Company Ltd	US$ 0.275 (-45.00%)	2.27M
LXRXLexicon Pharmaceuticals Inc	US$ 1.23 (-36.92%)	21M
VCIGVCI Global Ltd	US$ 0.0583 (-27.58%)	26.57M
ATHAAthira Pharma Inc	US$ 0.606 (41.56%)	239.63M
SQQQProShares UltraPro Short QQQ	US$ 7.44 (-2.11%)	216.16M
NVDANVIDIA Corporation	US$ 135.40 (1.99%)	209.27M
ELABElevai Labs Inc	US$ 0.0288 (-51.19%)	202.28M
INTCIntel Corporation	US$ 23.20 (7.81%)	173.47M